Medication info

Darim Ezetimibe Tablet 10 mg

Prescription medicationTabletExpired
Ingredient · strength
Ezetimibe›10mg / 1 tablet
Manufacturer / importer
Darim Biotech Co., Ltd.
Appearance
White to off-white rectangular tablet
Packaging
10 tablets/PTP, 30 tablets (10 tablets/PTP*3), 100 tablets/bottle
Approval status
Expired

MFDS item code 201900323 · Approved 2019.01.22

This product's status changed to Expired on 2024.01.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of hypercholesterolemia, mixed hyperlipidemia, and homozygous sitosterolemia
Who uses it
Adults
Adult dosage
A standard cholesterol-lowering diet should be continued while taking this medicine. The recommended dose of this medicine is 10 mg once daily, taken with or without food. When this medicine is administered concomitantly with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When this medicine is administered concomitantly with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use 4. General Precautions). Administration in patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use 2. Patients Requiring Caution in Administration). Administration in patients with renal impairment No dose adjustment is required in patients with renal impairment. Administration in older adults No dose adjustment is required when administering this medicine to older adults. Concomitant administration with bile acid sequestrants This medicine should be administered 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use 5. Interactions).

Ingredients

Manufacturer
Darim Biotech Co., Ltd.

Efficacy & effects

Improvement of hypercholesterolemia, mixed hyperlipidemia, and homozygous sitosterolemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • homozygous familial sitosterolemia
  • homozygous sitosterolemia
  • sitosterolemia
  • dyslipidemia
  • diabetes
  • hypothyroidism
  • obstructive liver disease
View approved original text

This medication is primarily used to lower cholesterol and lipid levels in patients with primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. It can first be used as an adjunct to dietary therapy to reduce total cholesterol, LDL cholesterol, and apolipoprotein B. Additionally, this medication may enhance the effect by combination with other lipid-lowering agents and is especially used as an adjunct to treatments such as LDL apheresis in familial hypercholesterolemia. In patients with sitosterolemia, it helps to reduce elevated plant sterol levels. Before using this medication, it is important to identify and treat secondary causes such as diabetes and hypothyroidism, and monitor treatment progress through regular lipid tests. Overall, this medication is effectively used to improve hypercholesterolemia and related lipid abnormalities.

Dosage and Administration

Adult dosage

A standard cholesterol-lowering diet should be continued while taking this medicine. The recommended dose of this medicine is 10 mg once daily, taken with or without food. When this medicine is administered concomitantly with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When this medicine is administered concomitantly with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use 4. General Precautions). Administration in patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use 2. Patients Requiring Caution in Administration). Administration in patients with renal impairment No dose adjustment is required in patients with renal impairment. Administration in older adults No dose adjustment is required when administering this medicine to older adults. Concomitant administration with bile acid sequestrants This medicine should be administered 2 hours before or 4 hours after administration of a bile acid sequestrant (see Precautions for Use 5. Interactions).

Precautions

This medication should not be used by patients with hypersensitivity to specific components. The combination of this medication with certain lipid-lowering agents is contraindicated in patients with severe liver dysfunction or persistently elevated liver enzyme levels of unknown cause. Women who are pregnant or breastfeeding are prohibited from using this medication in combination with certain lipid-lowering agents; therefore, women who may become pregnant should exercise caution. In patients with moderate to severe liver function impairment, this medication's exposure may increase, leading to unexpected adverse effects, so it must be used with caution. In clinical trials, this medication has been safe for most patients; however, side effects such as headache, abdominal pain, diarrhea, fatigue, and myalgia may occur. Particularly when this medication is used in combination with other lipid-lowering agents, there may be more frequent occurrences of elevated liver enzyme levels or muscle-related abnormal symptoms, hence regular testing is required. If symptoms of myalgia or muscle weakness occur, the doctor should be notified immediately, and dosing should be discontinued if necessary. Patients with severe renal impairment also require caution, and kidney function should be monitored before and after dosing. This medication can interact with other drugs, so patients must inform healthcare providers about any medications they are taking. In cases of pregnancy or breastfeeding, the potential risks and benefits of this medication should be carefully considered before use. In children under 6 years old, use is not recommended; however, children and adolescents over 6 years old show responses similar to adults but require caution. Elderly patients can generally use it safely, but individual sensitivity may vary, so caution is warranted. In cases of overdose, there is no specific antidote, so treatment should be based on symptoms, and it is important to keep it out of reach of children.

Side effects

  • Fatigue
  • abdominal pain
  • diarrhea
  • viral infection
  • pharyngitis
  • sinusitis
  • joint pain
  • low back pain
  • cough
  • chest pain
Show 58 more
  • dizziness
  • headache
  • constipation
  • distention
  • nausea
  • elevated AST
  • elevated ALT
  • myalgia
  • myopathy
  • rhabdomyolysis
  • hepatitis
  • thrombocytopenia
  • nausea
  • pancreatitis
  • paresthesia
  • depression
  • cholelithiasis
  • cholecystitis
  • chest pain
  • chest discomfort
  • edema
  • weakness
  • systemic edema
  • diabetic neuropathy
  • tremors
  • upper abdominal pain
  • vomiting
  • gastritis
  • dry mouth
  • epigastric discomfort
  • belching
  • gastrointestinal disturbances
  • gastroesophageal reflux disease
  • tongue disorders
  • palpitations
  • congestive heart failure
  • myocardial ischemia
  • flushing
  • sputum
  • runny nose
  • limb pain
  • diabetes
  • hypoglycemia
  • anemia
  • splenomegaly
  • urticaria
  • hyperhidrosis
  • rash
  • pruritus
  • upper respiratory infection
  • conjunctival injection
  • renal failure
  • abnormal liver function
  • increased serum creatinine
  • elevated blood pressure
  • increased serum urea
  • increased serum creatine phosphokinase
  • abnormal liver function tests

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. To maintain its efficacy, it is recommended to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White to off-white rectangular tablet

Package unit

10 tablets/PTP, 30 tablets (10 tablets/PTP*3), 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.